secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenon Pharmaceuticals Inc. (XENE)
CIK:        0001582313
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0000950170-23-062022
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenon partner Neurocrine's Phase 2 trial of NBI-921352 in focal seizures fails
------------------------------------------------------------------------------

- Phase 2 study of NBI-921352 in adult focal onset seizures failed to show meaningful seizure reduction.
- Neurocrine will not pursue further development of NBI-921352 in focal onset seizures.
- Xenon to review data for potential implications on ongoing SCN8A-developmental epileptic encephalopathy study.
- Neurocrine continues pre-clinical development of dual selective Nav1.2/1.6 inhibitor under collaboration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582313/000095017023062022/0000950170-23-062022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582313/000095017023062022/xene-20231109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-062022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer